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Members of the insulin/IGF superfamily are well conserved across the evolutionary tree. We 24 
recently showed that four viruses in the Iridoviridae family possess genes that encode proteins 25 
highly homologous to human insulin/IGF-1. Using chemically synthesized single chain (sc), i.e. 26 
IGF-1-like, forms of the viral insulin/IGF-1 like peptides (VILPs), we previously showed that they 27 
can stimulate human receptors. Because these peptides possess potential cleavage sites to form 28 
double chain (dc), i.e. more insulin-like, VILPs, in this study, we have characterized dc forms of 29 
VILPs for Grouper iridovirus (GIV), Singapore grouper iridovirus (SGIV) and Lymphocystis 30 
disease virus-1 (LCDV-1). GIV and SGIV dcVILPs bind to both isoforms of human insulin 31 
receptor (IR-A, IR-B) and to the IGF1R, and for the latter show higher affinity than human insulin. 32 
These dcVILPs stimulate IR and IGF1R phosphorylation and post-receptor signaling in vitro and 33 
in vivo. Both GIV and SGIV dcVILPs stimulate glucose uptake in mice. In vivo infusion 34 
experiments in awake mice revealed that while insulin (0.015 nmol/kg/min) and GIV dcVILP 35 
(0.75nmol/kg/min) stimulated a comparable glucose uptake in heart, skeletal muscle and brown 36 
adipose tissue, GIV dcVILP stimulated ~2 fold higher glucose uptake in white adipose tissue 37 
(WAT) compared to insulin. This was associated with increased Akt phosphorylation and glucose 38 
transporter type 4 (GLUT4) gene expression compared to insulin. Taken together, these results 39 
show that GIV and SGIV dcVILPs are active members of the insulin superfamily with unique 40 
characteristics. Elucidating the mechanism of tissue specificity for GIV dcVILP will help us to 41 
better understand insulin action, design new analogues that specifically target the tissues, and 42 
provide new insights into their potential role in disease.  43 
 44 
Key words: insulin, IGF-1, GLUT4, adipose tissue, glucose metabolism, viral mimicry  45 
 46 
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In vertebrates, the insulin gene superfamily includes insulin, two insulin-like growth 48 
factors (IGF-1 and IGF-2), and more distant hormones including relaxin and the Leydig insulin-49 
like peptides1. Insulin-like peptides have also been identified in invertebrates including insects, 50 
mollusks and nematodes2-5. These ligands are well conserved across the phylogenetic tree. 51 
However, their functions vary from the control of longevity and stress resistance in invertebrates 52 
to the control of metabolism and cell growth in vertebrates5. In mammals, insulin mainly regulates 53 
glucose and lipid metabolism6, whereas IGF-1 and IGF-2 control predominantly cell growth, 54 
proliferation and differentiation7. Insulin and IGF-1 bind to two different tyrosine kinase receptors 55 
in mammals – the insulin receptor, which itself exists in two isoforms (IR-A and IR-B), and the 56 
IGF-1 receptor (IGF1R)7.  Invertebrates, on the other hand, often have multiple insulin-like 57 
peptides and elicit their biological function through one receptor or in rare cases through multiple 58 
receptors2-4,8. A major difference between insulin and IGF-1/2 is their ability to be processed post-59 
transcriptional into either a two chain peptide hormone, in the case of insulin, or a single chain 60 
peptide hormone, in the case of IGF-1/2. 61 
We recently showed that four viruses that belong to Iridoviridae family possess genes that 62 
show significant homology to human insulin/IGF-1 which we termed viral insulin/IGF-1-like 63 
peptides or VILPs for short9,10. Although viruses encoding these sequences were originally isolated 64 
from fish11-14, reanalyzing published human microbiome data, we identified the DNA of some of 65 
these viruses in human fecal and blood samples9.  In our previous study, three VILPs were also 66 
chemically synthetized as single chain peptides (sc), i.e. IGF-1 like peptides, and we showed that 67 
scVILPs are weak ligands of the insulin receptor but strong ligands of the IGF-1 receptor in vitro 68 
and also possessed some glucose lowering effects in vivo9.  69 
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 In humans, insulin is initially translated as a single chain peptide (preproinsulin) in 70 
pancreatic β-cells containing a signal peptide (SP) followed by B-, C- and A-domains (Fig. 1, Fig. 71 
S1A). Proinsulin is formed in endoplasmic reticulum by cleavage of the SP, and the C-peptide is 72 
removed in the secretory granules to form mature insulin with A- and B- chains bound together by 73 
disulfide bonds15. Unlike insulin, IGF-1 is produced in multiple tissues, but primarily in the liver16, 74 
and after cleavage of the signal peptide remains as a single chain peptide consisting of A- and B-75 
domains, a short C-domain, and an additional D-domain at the C-terminus (Fig. 1A, Fig. S1B). 76 
The two peptide hormones show significant structural homology with about 50% of their amino 77 
acids being identical. Six cysteines that are crucial for the correct protein folding are also 78 
evolutionally conserved (Fig. S1). These cysteines are conserved throughout the phylogenetic 79 
tree5,17,18, and are considered to be a characteristic sign of the peptides belonging to the insulin/IGF 80 
peptide family. The main secondary structure motifs are also conserved between insulin and IGF-81 
1, including the central α-helix in the B-chain/domain and two antiparallel α-helices in the A-82 
chain/domain19,20.  83 
In this study, we have synthesized and characterized the double chain (dc, insulin-like) 84 
forms of three VILPs - Grouper Iridovirus (GIV), Singapore Grouper Iridovirus (SGIV) and 85 
Lymphocystis disease virus-1 (LCDV-1) VILPs - for the first time.  Using in vitro assays, we show 86 
that both GIV and SGIV dcVILPs can bind to both isoforms of the human insulin receptor and 87 
human IGF1R and stimulate post-receptor signaling, while LCDV-1 dcVILP is a very weak ligand. 88 
GIV and SGIV dcVILPs can also stimulate glucose uptake in vivo. During in vivo infusion 89 
experiments in awake mice, GIV dcVILP preferentially stimulates glucose uptake in white adipose 90 
tissue (WAT) compared to other insulin sensitive tissues. This is associated with higher Akt 91 
phosphorylation and expression of GLUT4 gene upon GIV dcVILP stimulation in WAT compared 92 
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to insulin. Taken together, our results show that GIV and SGIV dcVILPs are potent members of 93 
insulin/IGF family and GIV dcVILP has unique WAT specific characteristics.  94 
 95 
RESULTS 96 
dcVILPs show significant homology in primary and predicted 3D structures with human 97 
insulin and IGF-1 98 
Comparative alignment analysis revealed that GIV, SGIV and LCDV-1 dcVILPs show 99 
significant homology with human insulin and IGF-1 (Table 1. Fig. S1). All VILPs carry the six 100 
cysteine residues that form intrachain and interchain disulfide bonds and are critical for correct 101 
folding of insulin/IGF-like molecules (Fig. S1). While GIV and SGIV dcVILPs only differ in three 102 
amino acids within their A- and B-chains, the similarity between LCDV-1 and GIV/SGIV 103 
dcVILPs is lower with LCDV-1 sharing only 40% of amino acids of the A- and B-chains with GIV 104 
and SGIV dcVILPs (Fig. S1). A significant number of the residues that have been previously 105 
shown to be involved in insulin:IR or IGF-1:IGF1R interaction21-26 are either conserved or 106 
conservatively substituted in dcVILPs (Fig. 1A, Table 1). Structural studies have suggested that 107 
the mature IR or IGF1R can bind with high affinity two insulin or IGF-1 molecules effectively 108 
crosslinking two binding subsites on IR/IGF1R named as Site 1 and Site 221-23,27-29. However, two 109 
recent studies suggested that up to four insulin molecules can bind to IR24,25 via two distinct 110 
binding sites. Uchikawa et. al.24 named the new binding site as “Site 2”, while they named 111 
previously identified sites as Site 1. In this manuscript, we used this new Site 1 and Site 2 112 
nomenclature for IR binding. Interestingly, no analogic binding site to the new IR site 2 was 113 
identified in IGF1R26. Significant number of residues that are critical in receptor binding are 114 
conserved or conservatively substituted in dcVILPs (Fig. 1A, Table 1). To explore the similarity 115 
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of 3D structures of dcVILPs with insulin, IGF-1 and its potential effect on binding to IR and 116 
IGF1R, we created models of dcVILPs bound to these receptors. These models indicate that 117 
residues conserved among dcVILPs, insulin and IGF-1 take similar positions upon receptor 118 
binding. Insulin and IGF-1 bound to Site 1 of IR/IGF1R, respectively, and the predicted structures 119 
of GIV and LCDV-1 dcVILPs bound to Site1 of the receptors are shown in Fig. 1B-E 120 
 121 
GIV and SGIV dcVILPs bind to the human insulin and IGF-1 receptors  122 
To determine the relative affinity of dcVILPs for the two isoforms of human insulin 123 
receptor (IR-A and IR-B) and the IGF-1 receptor, we tested their ability to compete with 125I-124 
Insulin and 125I-IGF-1 in a binding competition assay30,31. We used IM-9 lymphoblasts for IR-A 125 
binding competition since these cells exclusively express IR-A on their surface32,33. Murine 126 
embryonic fibroblasts cells derived from IGF1R knock-out mice34 stably transfected with either 127 
human IR-B or human IGF1R were used to assess binding competition for IR-B and IGF1R35,36.  128 
Consistent with previous studies37, we find that human IGF-1 binds to IR-A and IR-B with ~200x 129 
and ~300x lower affinity than human insulin, respectively.  GIV dcVILP competes for binding to 130 
IR-A with an affinity ~3x lower than human IGF-1, while the affinity of SGIV dcVILP was 131 
comparable to IGF-1. The relative affinity of the GIV and SGIV dcVILPs for IR-B was slightly 132 
lower, with ~7-8x lower for both dcVILPs compared to IGF-1. Although LCDV-1 dcVILP has 133 
more identical residues to insulin than GIV and SGIV dcVILPs, we did not observe any binding 134 
competition with this ligand (Fig 2A and B, Table 2). The affinity of insulin for IGF1R was 135 
~1000x lower compared to IGF-1, consistent with previous studies37. Thus, even as double chain 136 
peptides, GIV and SGIV dcVILPs had higher affinity for IGF1R than insulin by 7- to 10-fold. We 137 
did not observe any binding competition for LCDV-1 dcVILP for IGF1R (Fig 2C, Table 2). 138 
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dcVILPs stimulate downstream insulin/IGF-1 signaling via human IR-A, IR-B and IGF1R 139 
To explore the effects of the dcVILPs on post-receptor signaling, we used the murine 140 
embryonic fibroblasts defined above that overexpress either human IR-A, IR-B or IGF1R35,36. 141 
Insulin/IGF-1 acting through their respective receptors activate (i) the PI3K/Akt pathway, that 142 
mainly regulates metabolic effects, and (ii) the Ras/MAPK pathway, that is responsible for 143 
mitogenic effects38,39. We tested receptor phosphorylation and phosphorylation of Akt for 144 
PI3K/Akt pathway activation and Erk1/2 for Ras/MAPK pathway activation.  145 
 146 
On both IR isoforms, insulin induced the strongest dose-response for stimulation of the 147 
receptor autophosphorylation as expected. IGF-1 was less potent such that stimulation with 250 148 
nM ligand was weaker than insulin at 10 nM (Fig. 2D and E). GIV and SGIV dcVILPs stimulated 149 
insulin/IGF signaling in a dose-dependent manner. On IR-A, SGIV dcVILP stimulated receptor 150 
phosphorylation comparable to IGF-1, and GIV dcVILP was slightly less potent at all 151 
concentrations tested (Fig. 2D). On IR-B, both peptides were slightly less potent compared to IGF-152 
1 and comparable to each other (Fig. 2E). Both GIV and SGIV dcVILP stimulated phosphorylation 153 
of Akt and Erk1/2 in proportion to their effects on the receptor with greater effects on IR-A than 154 
IR-B (Fig. 2D and 2E). Although we did not observe any competition for binding with LCDV-1 155 
dcVILP, we observed a weak Akt and receptor autophosphorylation on both IR-A and IR-B (Fig. 156 
2F). Consistent with the binding competition results on IGF1R, SGIV and GIV dcVILPs 157 
stimulated post-receptor signaling more potent than insulin, with SGIV dcVILP being slightly 158 
more potent than GIV dcVILP. As observed for the IR, although we did not observe any binding 159 
competition for LCDV-1 dcVILP, it stimulated a weak signal for receptor and Akt phosphorylation 160 
(Fig. 2F). 161 
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GIV and SGIV dcVILPs are active in vivo and stimulate glucose uptake in mice 162 
To test whether dcVILPs can stimulate glucose uptake in vivo, we performed an insulin 163 
tolerance test (ITT). Adult C57BL/6J mice were injected intraperitoneally with either 6 nmol/kg 164 
insulin or different concentrations of GIV and SGIV dcVILPs (Fig. 3). Based on our in vitro data 165 
showing about 0.05 % relative affinity for the IR, we decided to use 0.3 µmol/kg (50x higher 166 
concentration than insulin) GIV and SGIV dcVILPs in male mice. Consistent with previous 167 
studies9,40, insulin caused ~ 60% decrease in blood glucose in 60 minutes, after which glucose 168 
started to increase.  Surprisingly, injection with 50x GIV or SGIV dcVILPs led to very severe 169 
hypoglycemia such that we needed to terminate the experiment in 30 minutes by injecting glucose 170 
to save the animals (Fig. 3A).  171 
When this experiment was repeated using 60 nmol/kg concentrations of the dcVILPs (10x) 172 
(Fig. 3B and D), again, both dcVILPs were able to significantly lower the blood glucose, and at 173 
60 minutes produced 57-58% of the effect of insulin (Fig. 3B). By comparison, injection of IGF-174 
1 at 60 nmol/kg concentration (10x ) reached 71% of the effect of insulin at 60 min, and this effect 175 
persisted for longer than insulin’s effect consistent with the longer half-life of IGF-1 compared to 176 
insulin (Fig. 3C). Similar results were obtained in female mice (Fig. 3D). Taken together, these 177 
results indicate that both dcVILPs have in vivo glucose lowering effects similar to IGF-1, but 178 
slightly more than an order of magnitude less potent than insulin and with a longer duration of 179 
effect. 180 
 181 
In vivo infusion experiments reveal white adipose tissue specific effects of GIV dcVILP  182 
To further explore the mechanism of dcVILP action in vivo, we performed an in vivo 183 
experiment using an acute administration of GIV dcVILP in awake mice. In this experiment, male 184 
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C57BL/6J mice were intravenously infused with constant levels of tested ligand or insulin for 2 185 
hours, and 20% glucose was infused at variable rates to maintain euglycemia. We first optimized 186 
the conditions using a 0.015nmol/kg/min dose for insulin and 0.15 nmol/kg/min (10x) and 1.5 187 
nmol/kg/min (100x) for GIV dcVILP. GIV dcVILP at 100x induced a strong glucose disposal as 188 
reflected by a profound increase in glucose infusion rate during the experiments, and there was a 189 
dose-dependent effect of GIV dcVLIP as shown by a minimal effect of GIV dcVILP at 10x on 190 
glucose disposal in mice (Fig 3E). Based on this dose optimization experiment, we performed a 191 
3-hour infusion of 0.75 nmol/kg/min (50x) concentration of the GIV dcVILP and compared the 192 
effects to a 3-hour infusion of insulin at 0.015 nmol/kg/min in awake mice. Our data indicate that 193 
GIV dcVILP at 50x induced an increase in glucose disposal similar to insulin, as reflected by 194 
comparable rates of glucose infusion during the 3-hour experiments (Fig. 3F). 195 
In additional cohort of mice, we performed a 3-hour infusion of 0.75 nmol//kg/min (50x) 196 
concentration of the GIV dcVILP or insulin at 0.015 nmol/kg/min with a continuous infusion of 197 
[3-3H]glucose to assess whole body glucose turnover, and 2-deoxy-D-[1-14C]glucose was 198 
administered as a bolus at 45 min before the end of experiments to measure glucose uptake in 199 
individual organs. Measurements of glucose uptake in heart, skeletal muscle (gastrocnemius), 200 
brown adipose tissue (BAT, intrascapular) and white adipose tissue (WAT, epididymal) identified 201 
a unique characteristic of GIV dcVILP. While GIV dcVILP (50x) stimulated a comparable glucose 202 
uptake compared to insulin in gastrocnemius muscle, heart and BAT (Fig. 4A-C)., the glucose 203 
uptake was significantly (1.9 fold) increased in WAT compared to insulin (Fig. 4D). This finding 204 
suggests a tissue selective effect for GIV dcVILP on glucose metabolism in white adipose tissue.  205 
Hepatic glucose production was significantly suppressed in both insulin and GIV dcVILP 206 
groups but we did not determine any significant difference related to insulin action in the liver 207 
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(Table S1). In separate experiments, we assessed insulin signaling in liver, gastrocnemius muscle 208 
and WAT and found that 50x GIV dcVILP stimulated phosphorylation of IR/IGF1R and Akt in 209 
all tissues (Fig. 4E-G, Fig. S2).  Akt phosphorylation was significantly increased by GIV dcVILP 210 
in the liver (p=0.0036) and WAT (p=0.0009) compared to the insulin group (Fig. S2B, F).  211 
 212 
GIV dcVILP induces GLUT4 gene expression in WAT in vivo  213 
To further understand the tissue selective effects of the GIV dcVILP observed for WAT, 214 
we used tissues collected at the end of a 3-hour in vivo infusion of GIV VLIP or insulin in awake 215 
mice to evaluate the expression of the receptors and insulin-stimulated genes. Basal tissue samples 216 
were collected from mice after a 3-hour infusion of saline. Because our in vitro data showed that 217 
GIV dcVILP stimulates IGF1R more than insulin, we first explored the possibility that the GIV 218 
dcVILP specific glucose uptake is caused by different receptor composition in different tissues. 219 
Using RT-qPCR, we showed that liver, BAT and WAT contain the highest amount of IR-B and 220 
low amounts of IR-A and IGF1R. In contrast, the most abundant receptor in skeletal muscle was 221 
IR-A (Fig. S3). These results showed that higher glucose uptake is not related to increased IGF1R 222 
expression in WAT. Next, we evaluated the expression of genes related to insulin action in liver, 223 
skeletal muscle (quadriceps), BAT and WAT. Specifically, we focused on the genes related to 224 
glucose metabolism and lipogenesis. We also tested GLUT4 in all four tissues, and thermogenesis 225 
marker uncoupling protein 1 (UCP-1) in BAT.  226 
 Consistent with our findings from in vivo glucose uptake, GLUT4 expression was 227 
significantly higher (1.5 fold) in GIV dcVILP-stimulated WAT compared to insulin-stimulated 228 
WAT (Fig. 5A). In addition to GLUT4, fatty acid synthase (FASN) expression was increased by 229 
2.1 fold in GIV dcVILP compared to insulin (Fig. 5B). Insulin and GIV dcVILP stimulated sterol 230 
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regulatory element-binding protein 1-C (SREBP-1c) expression in a similar manner (Fig. 5C), 231 
while GIV dcVILP showed an increasing trend for acetyl-CoA carboxylase 1 (ACACA) 232 
expression compared to insulin (p=0.087, Fig. 5D). We did not observe any significant differences 233 
between insulin and GIV dcVILP stimulated gene expression in any of the genes tested in muscle 234 
(Fig. S4) and BAT (Fig. S5). 235 
Consistent with previous studies on insulin action in the liver41, the gluconeogenesis 236 
markers, catalytic subunit of glucose-6-phospgatase (G6PC) and phosphoenol pyruvate 237 
carboxykinase 1 (PCK1), were downregulated by both insulin and GIV dcVILP (Fig. 6A and B), 238 
while glucokinase (GCK), the glycolysis marker, was upregulated (Fig. 6C). Interestingly, we 239 
observed a significant (1.6 fold) increase for GCK in the GIV dcVILP group compared to the 240 
insulin group.  The lipogenesis markers were decreased by both insulin and GIV dcVILP (Fig. 6D-241 
G). Although, the GLUT4 expression is very low in the liver42, we observed a significant increase 242 
in GLUT4 expression after stimulation by GIV dcVILP when compared to both saline as well as 243 
insulin (4.7 fold) (Fig. 6H). When we analyzed the receptor expression, both insulin and GIV 244 
dcVILP downregulated IR-B expression in the liver (Fig. 6I), whereas only GIV dcVILP 245 
downregulated IGF1R expression (Fig. 6J).  246 
DISCUSSION 247 
We recently discovered that four viruses belonging to the Iridoviridae family possess genes 248 
with high homology to human insulin and IGFs9. In this study, we characterized three of these 249 
VILPs in their insulin-like, i.e. double-chain, forms for the first time. We first showed that GIV 250 
and SGIV dcVILPs can bind to IR-A, IR-B and IGF1R. Interestingly, on IR-A, the affinity of 251 
SGIV dcVILP is comparable to that of IGF-1, whereas the affinity of GIV dcVILP is ~ 3x lower. 252 
On IR-B, however, the affinities of GIV and SGIV dcVILPs are comparable to each other and ~ 253 
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7-8x lower than IGF-1. The only difference between IR-A and IR-B is 12 extra amino acids in the 254 
α-CT peptide that are present in IR-B but not IR-A32,35.  This α-CT peptide is directly involved in 255 
ligand binding21,22,24,25.  256 
The sequences of GIV and SGIV dcVILPs differ only in three amino acids (Fig. S1), which 257 
correspond to insulin residues ValB2, ProB28 and SerA12. ValB2 and ProB28 have not been 258 
shown to be involved in the insulin:IR interaction, whereas SerA12 was shown to be involved in 259 
the Site 2 interaction24,25. SerA12 substitution by alanine decreases the affinity to IR to 36% of 260 
insulin27, however, SerA12 is known to be involved in interaction within IR FnIII-1 domain24,25 . 261 
Therefore, SerA12 is unlikely to play a role in the differential binding to IR-A and IR-B. The only 262 
residue that lies in a region that is involved in interaction with the α-CT peptide (specifically C-263 
terminal region of insulin B-chain21,24,25) is the residue corresponding to insulin ProB28. This 264 
residue is substituted by serine in GIV dcVILP and proline in SGIV dcVILP. Therefore, it is 265 
probable that the ProB28Ser substitution lies behind the decreased affinity of GIV dcVILP to IR-266 
A compared to SGIV dcVILP. By modeling of GIV and SGIV dcVILPs onto Site 1 of IR, we 267 
showed that the ProB28 presence makes the following ArgB28 and ArgB29 direct to the α-CT 268 
helix segment in SGIV dcVILP, while these residues are directed away from it in GIV dcVILP 269 
(Fig. S6A). Importantly, the last receptor amino acid in the model is Arg717 (PDB 6PVX) which 270 
is the last amino acid that is identical in IR-A and IR-B. After Arg717, there are three additional 271 
amino acids in IR-A, while there are 15 more amino acids in IR-B that are not present in the model. 272 
Therefore, GIV dcVILP would potentially clash with the following α-CT sequence in both IR-A 273 
and IR-B, while SGIV dcVILP would avoid this clash in IR-A, but would still clash with the longer 274 
IR-B. This may explain why SGIV dcVILP has three-fold higher affinity for IR-A than GIV 275 
dcVILP, while their affinity for IR-B is comparable. 276 
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Another interesting observation is that GIV and SGIV dcVILPs have higher affinity to bind 277 
and stimulate signaling via IGF1R than insulin, since these ligands are missing the C-domain that 278 
is important for IGF-1:IGF1R interaction43-46. Even though dcVILPs are completely missing the 279 
C-domain, they bind to IGF1R with 7x (GIV dcVILP) and 10x (SGIV dcVILP) higher affinity 280 
compared to insulin. Signaling experiments are consistent with the binding results and showed a 281 
similar trend as both GIV and SGIV dcVILPs stimulated phosphorylation of IGF1R, Akt and Erk 282 
with higher potency than insulin.  The comparison of amino acid sequences of GIV and SGIV 283 
dcVILPs with insulin and IGF-1 revealed that several amino-acids that are involved in insulin 284 
binding to the Site 2 of IR are replaced in these VILPs by amino acids that are identical to IGF-1 285 
in the corresponding positions - and differ from insulin. Specifically, these include GluB10 286 
(corresponding to Glu9 in IGF-1 and HisB10 in insulin), AspB13 (corresponding to Asp12 in IGF-287 
1 and GluB13 in insulin) and AspB21 (corresponding to Asp20 in IGF-1 and GluB21 in insulin) 288 
(Fig 1A). Interestingly, two of these three residues in IGF-1 (Glu9 and Asp12) are involved in 289 
IGF1R Site 1 binding.  Comparisons of these two residues in models of GIV bound to the Site 2 290 
of IR and Site 1 of IGF1R to human insulin (Fig. S6B) and IGF-1 (Fig. S6C) indicate that GIV 291 
and SGIV dcVILPs might preferentially bind to the Site 1 of IGF1R than to Site 2 of IR. This may 292 
be a possible explanation of why GIV and SGIV dcVILPs show an increased affinity and ability 293 
to activate IGF1R than insulin. Moreover, the HisB10Glu/Asp mutation in insulin is itself well 294 
known for dramatically enhancing the binding affinity to both IGF1R and IR-A47-49. 295 
One of the most interesting findings of this study is related to analysis of glucose uptake in 296 
the in vivo infusion experiments. We showed that GIV dcVILP (50x) specifically stimulates ~2 297 
fold glucose uptake in epididymal white adipose tissue compared to insulin. We first explored the 298 
distribution of the receptors in insulin sensitive tissues, but we did not observe an increased 299 
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expression of IGF1R in WAT. Because we determined an increased Akt phosphorylation for GIV 300 
dcVILP compared to insulin in WAT, we decided to investigate the genes related to insulin action. 301 
We observed an increased GLUT4 and FASN expression in the GIV dcVILP group compared to 302 
insulin. This was specific to WAT and not observed in BAT and skeletal muscle. In liver, 303 
glucokinase was significantly increased in mice receiving GIV dcVILP compared to insulin. The 304 
increase in glucokinase might be related with using an increased dose of GIV dcVILP compared 305 
to insulin. 306 
Our results on GLUT4 expression are particularly interesting. Since its discovery in 198850, 307 
there have been tremendous efforts to understand the function and regulation of GLUT451. Insulin 308 
is known to stimulate GLUT4 translocation51,52, but not GLUT4 expression. Our data show that 309 
GIV dcVILP significantly stimulates GLUT4 expression in WAT. Further, both insulin and GIV 310 
dcVILP stimulated GLUT4 expression in BAT. These results indicate that GLUT4 expression in 311 
adipose tissue can be regulated by specific insulin analogues. It is previously shown tht GLUT4 312 
expression is decreased in obesity and increased in response to exercise adipocytes53. Further, 313 
overexpression of GLUT4 in adipose tissue makes mice more insulin sensitive and glucose 314 
tolerant54,55. Thus, identification and synthesis of novel insulin analogues targeting GLUT4 315 
expression in adipose tissue might be a novel approach to be tested in diabetes control in the future. 316 
According to our knowledge, GIV dcVILP is the first insulin analogue that has WAT 317 
specificity and further studies are needed to explain the specific mechanism underlying the tissue-318 
selectivity. Previous studies have identified hepatoselective action for different insulin 319 
analogues56-61. This selectivity is thought to be related with either increased molecular size 320 
(proinsulin and insulin peglispro) or their ability to bind endogenous proteins (thyroxyl conjugates 321 
and insulin detemir)62.  The increased data produced by genome projects have increased our ability 322 
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to understand the natural repertoire of hormone ligands. For example, the Gila monster exendin-4 323 
mimics GLP-1 functions and unlike human GLP-1, it has a long half time63,64. Likewise, recent 324 
discovery of cone snail venom insulins have potential to help us designing fast-acting insulin 325 
analogues65-67 . Thus, characterization of new VILPs that are evolved as a result of host-pathogen 326 
interactions, and understanding the characteristics of tissue specificity, has potential to help us 327 
design better insulin therapies.  328 
In our previous study, we showed that the sequences of these VILP-carrying viruses are 329 
identified in human fecal and plasma samples9. Although this finding suggests that humans are 330 
exposed to these viruses, it is still unclear whether these fish viruses can infect humans. While we 331 
continue to work on this question, if they do infect humans, this will raise several questions 332 
regarding their link to human disease including diabetes, cancer and hypoglycemia. While the 333 
number of viruses that can infect mammalian animals are predicted to be over 320,00068, there are 334 
only 10,316 complete viral genomes in the NCBI database as of August 1, 2020. Thus, we expect 335 
to identify human viruses carrying VILPs in the future. Human viruses are known to target cellular 336 
metabolism by changing the expression levels of transcription factors, metabolic intermediates and 337 
enzymatic activity69-72. We anticipate that VILP carrying viruses are targeting the glucose 338 
metabolism and cell cycle when they infect fish to promote their replication. Furthermore, insulin 339 
and IGF-1 are mitogenic and anti-apoptotic molecules73 that are two perfect characteristics that a 340 
pathogen needs. Indeed, overexpression of SGIV VILP stimulated cell proliferation in fish cells 341 
and increased SGIV replication74. 342 
Taken together, our study shows that GIV and SGIV dcVILPs are new members of the 343 
insulin/IGF superfamily with remarkable in vitro and in vivo insulin/IGF-1 like effects. Although 344 
we could not show binding competition for LCDV-1 dcVILP to human IR and IGF1R, it can 345 
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stimulate a weak signal that needs further investigation.  Identification of tissue selectivity of GIV 346 
dcVILP has potential to help us to better understand the tissue selectivity of insulin.  Furthermore, 347 
the effects of GIV dcVILP on GLUT4 expression opens a new avenue to better understanding of 348 
Glut4 regulation by insulin action. In summary, our findings contribute to our understanding of 349 
VILP action on human receptors and have potential to help with designing new insulin/IGF 350 
analogs specific to WAT.   351 
 352 
  353 
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MATHERIALS AND METHODS  354 
Bioinformatics 355 
The sequence alignments presented in this paper were prepared using a multiple sequence 356 
alignment program (Clustal Omega). We used the website https://swissmodel.expasy.org/ for the 357 
homologous building75, and to align the modelled dcVILPs with insulin or IGF-1 in IR (PDB: 358 
6PXV) or IGF1R structures (PDB: 6PYH). The final figures prepared using PyMOL. 359 
Peptide synthesis 360 
Viral insulin-like peptides were synthesized via Fmoc solid phase peptide synthesis (SPPS) 361 
utilizing a commercial automated peptide synthesizer (Symphony® X, Gyros Protein 362 
Technologies) using a similar method to what has been previously reported76 .  Briefly, A- and B-363 
chains were individually synthesized at a 0.1 mmol scale using standard Fmoc protected amino 364 
acids, a specific set of orthogonally side-chain protected cysteine residues that allows for directed 365 
disulfide bridge formation, pseudoproline and isoacyl dipeptide building blocks that aid in 366 
overcoming coupling difficulties during SPPS and ameliorate solubility issues during HPLC 367 
purification, respectively.  Fmoc deprotection was carried out using 20% Piperidine in DMF, and 368 
coupling reactions were done using DIC/Oxyma for 1 hour using a 9-fold excess of reagents. 369 
Fmoc-Rink-MBHA resin was used as the solid support for the synthesis of the A-chains. The 370 
Cysteine protection arrangement used for GIV and SGIV dcVILPs A-chains was as follows:  371 
Cys(StBu)A6, Cys(Acm)A7, Cys(Mmt)A11, and Cys(Trt)A20.  The Cysteine protection 372 
arrangement used for LCDV-1 dcVILP A-chain was as follows: Cys(STmp)A6, Cys(Acm)A7, 373 
Cys(Mmt)A12, and Cys(Trt)A21. While no isoacyl dipeptides were used for GIV and SGIV 374 
dcVILPs A-chains, the LCDV-1 dcVILP A-chain required the use of Boc-Thr(Fmoc-Ala)-OH 375 
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isoacyl dipeptide at positions A3,4 and Fmoc-Thr(tBu)-Thr(ψMe,MePro)-OH pseudoproline 376 
dipeptide at positions A8,9 and A13,14.  A-chains are synthesized bearing the intramolecular 377 
disulfide bridge (CysA6-CysA11 for GIV and SGIV dcVILPs and CysA6-CysA12 for LCDV-1). 378 
Said bond was formed during the SPPS process as outlined in scheme 2 as reported by Liu et al.76 379 
. A slight deviation from scheme 2 was necessary for the synthesis of LCDV-1 dcVILP A-chain 380 
in that Cys(STmp)A6 was deprotected with 0.1 M N-methylmorpholine  and 5% dithiothreitol in 381 
DMF instead of 25% β-mercaptoethanol in DMF. B-chains for GIV and SGIV dcVILPs were 382 
synthesized on Fmoc-Arg(Pbf)-Wang resin and the B-chain for LCDV-1 dcVILP was carried out 383 
using H-Thr(tBu)-HMPB-ChemMatrix resin. The Cysteine protection arrangement used for GIV, 384 
SGIV and LCDV-1 dcVILPs B-chains was as follows:  Cys(Acm)B7, and  Cys(Trt)B19. While 385 
no isoacyl dipeptide was used for the LCDV-1 dcVILP B-chain, GIV and SGIV dcVILPs B-Chains 386 
included the use of Boc-Thr[Fmoc-Tyr(tBu)]-OH isoacyl dipeptide at positions B25,26.  The final 387 
solid support cleavage and global side chain deprotection is achieved using standard trifluoroacetic 388 
acid (TFA) mediated acidolysis protocols, with the inclusion of DTNP in the cleavage cocktail of 389 
the B-chains to afford the activated Cys(SNpy)19 residue .  The A- and B-chains were purified 390 
using standard reverse phase HPLC methods (TFA acidified water/acetonitrile mobile phases) and 391 
were lyophilized to dryness after purification. The intermolecular disulfide bridges CysA20-392 
CysB19, ACys7-CysB7 for GIV and SGIV dcVILPs; and CysA21-CysB19, CysA7-CysB7 for 393 
LCDV-1 dcVILPs were formed in a guided and sequential manner exploiting the orthogonality of 394 
the cysteine protection scheme.  A-chains, B-chains, intermediates, as well as the final dcVILPs 395 
were characterized by analytical LC-MS, purified by RP-HPLC and lyophilized to dryness. 396 
Cell culture 397 
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Human IM-9 lymphocytes (ATCC) and murine embryonic fibroblasts, that were derived from 398 
IGF1R knockout mice and stably transfected with either IR-A (R-/IR-A cells), IR-B (R-/IR-B cells) 399 
or IGF1R (R+39 cells), kindly provided by A. Belfiore (Catanzarro, Italy) and R. Baserga 400 
(Philadelphia, PA), were cultured as described previously30,77. 401 
Receptor binding studies 402 
For receptor binding studies, human IM-9 lymphoblasts, that express IR-A exclusively, and R-/IR-403 
B and R+39 murine embryonic fibroblasts (described above) were used for a whole-cell receptor-404 
binding assay. Receptor binding assays with IR-A were perfomed accoding to Morcavallo et al.30 405 
and binding assays with IR-B and IGF1R were performed according to Kosinova et al.31. The 406 
binding curve of each ligand was determined in duplicate, and the final dissociation constant (Kd) 407 
was calculated from at least three (n ≤ 3) binding curves. Human insulin and human IGF-1 were 408 
supplied by Merck . Human 125I-insulin (NEX420050UC) and human 125I-IGF-1 (NEX241025UC) 409 
were supplied by Perkin-Elmer.  410 
Receptor phosphorylation and downstream signaling 411 
For receptor phosphorylation and downstream signaling experiments, R-/IR-A, R-/IR-B and R+39 412 
murine embryonic fibroblasts (described above) were used to explore signaling properties of 413 
ligands via specific receptors. Cells were seeded into 24-well plates (Denville Scientific) (8x104 414 
cells per well) in 300 µl of DMEM media (Corning) and grown overnight. Afterwards, cells were 415 
washed twice with PBS and starved in serum-free media for 4 hours. After the starvation, cells 416 
were washed with pure DMEM media and incubated with ligand diluted in pure DMEM media (0, 417 
1, 10, 100 and 250 nM) in 37°C for 15 min. The reaction was terminated by washing the cells with 418 
ice-cold PBS (HyClone) followed by snap freezing in liquid nitrogene. Cell lysis was performed 419 
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using 50 µl of RIPA buffer (Millipore) supplemented with protease and phosphatase inhibotors 420 
(Bimake). Cells on plates were incubated in the RIPA buffer on ice for 15 minutes, then transferred 421 
to microtubes and incubated on ice for additional 15 minutes. The lysates were centrifuged (13 422 
000g, 5 min, 4°C) and supernatant was transferred to new microtubes. Protein concentration in 423 
each sample was evaluated using BCA Assay (Thermo Fisher Scientific). Samples were further 424 
diluted using sample buffer for SDS-PAGE (final concentration 62.5 mM Tris, 2% SDS (w/v), 425 
10% glycerol (v/v). 0.01% bromphenol blue (w/v), 0.1M DTT (w/v), pH = 6.8 (HCl)) and routinely 426 
analyzed using SDS-PAGE and immunoblotting. Cell lysates (4 µg of protein content/sample) 427 
were separated on 10% polyacrylamide gels and electroblotted to PVDF membrane. The 428 
membranes were probed with primary antibodies against phospho-IR/IGF1R (1:500, #3024), 429 
phospho-Akt (S473) (1:1000, #9271) and phospho-Erk1/2 (T202/Y204) (1:5000, #9101). All 430 
primary antibodies against phospho-proteins were purchased from Cell Signaling Technology. The 431 
western blots were developed using SuperSignal West Pico PLUS Sensitivity substrate (Thermo 432 
Fisher Scientific). For detection of the amount of total proteins, standard stripping procedure using 433 
the mild stripping buffer (1.5% glycine (w/v), 0.1% SDS (w/v), 1% Tween20 (v/v), pH=2.2 (HCl)) 434 
was used and the membranes were relabeled with primary antibodies against IRβ (1:1000, #3025), 435 
IGF1Rβ (1:1000, #9750), Akt (1:1000, #4685) and Erk1/2 (1:2000, #9102). All primary antibodies 436 
against total proteins were purchased from Cell Signaling Technology. HRP Goat Anti-Rabbit 437 
secondary antibody was used in all cases (1: 10000, ABclonal #AS014). 438 
Insulin tolerance test 439 
All animal studies presented in this study complied with the regulations and ethics guidelines of 440 
the NIH and were approved by the Boston College Institutional Animal Care and Use Committee. 441 
Insulin tolerance testing was performed on 12 to 20-week-old male C57BL/6J mice (Jackson 442 
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Laboratory). Mice were grouped according to their weight before experiment. After 4-hour 443 
starvation, mice were injected i.p. with insulin (Humulin, 6 nmol/kg (corresponds to 1.0 U/kg) (Eli 444 
Lilly), GIV and SGIV dcVILPs (0.3 µmol/kg or 60 nmol/kg), LCDV-1 dcVILP (1 µmol/kg) and 445 
saline as a control (n = 5 per condition). Tail-vein blood glucose was measured at the indicated 446 
time points (Fig. 3) using an Infinity glucometer (US Diagnostic Inc.). Statistical analysis was 447 
done using Mixed effects analysis - Dunnett’s multiple comparisons test. 448 
In vivo infusion experiments in awake mice 449 
All in vivo infusion experiments in mice were conducted at the National Mouse Metabolic 450 
Phenotyping Center (MMPC) at UMass Medical School, and animal studies were approved by the 451 
Institutional Animal Care and Use Committee of the University of Massachusetts Medical School. 452 
Male C57BL/6J mice received a survival surgery to establish an indwelling catheter in the right 453 
internal jugular vein. After recovery of 4-5 days, mice were fasted overnight (~16 hours) and 454 
placed in rat-sized restrainers for in vivo experiments. In the dose optimization experiment, mice 455 
received a continuous infusion of insulin (0.015 nmol/kg/min, corresponds to 2.5 mU/kg/min, n=4) 456 
or GIV (0.15 nmol/kg/min or 1.5 nmol/kg/min, n=2 for each group) for 2 hours, and 20% glucose 457 
was infused at variable rates to maintain euglycemia. Blood samples were collected from the tail 458 
tip at 10 min intervals to measure plasma glucose levels during the 2-hour experiments.The 459 
experiment was later repeated using continuous infusion the same concentration of insulin (0.015 460 
nmol/kg/min, n = 4), GIV dcVILP (0.75 nmol/kg min, n = 4) or saline (n = 4).   461 
Additional cohort of male C57BL/6J mice received a continous infusion of insulin (0.015 462 
nmol/kg/min, n=5), GIV dcVILP (0.75 nmol/kg/min, n = 5) or saline (n=6) for 3 hours, and 20% 463 
glucose was infused at variable rates to maintain euglycemia. During the experiments, [3-464 
3H]glucose (PerkinElmer, Waltham, MA) was continuously infused for 3 hours to assess whole 465 
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body glucose turnover, and 2-deoxy-D-[1-14C]glucose was administered as a bolus (10 μCi) at 45 466 
min before the end of experiments to measure glucose uptake in individual organs78. Blood 467 
samples were collected from the tail tip at 10-20 min intervals during the experiments. At the end 468 
of experiments, mice were euthanized, and tissues (skeletal muscle, liver, brown and white adipose 469 
tissue and heart) were harvested, snap frozen in liquid nitrogen and kept at -80°C for biochemical 470 
analysis. Statistical analysis was done using Two-way repeated measures ANOVA followed by 471 
Tukey’s multiple comparisons test. 472 
Biochemical analysis of glucose metabolism 473 
Glucose concentrations were analyzed using 5 μl plasma by a glucose oxidase method on 474 
Analox GM9 Analyser (Analox Instruments Ltd., Hammersmith, London, UK). Plasma 475 
concentrations of [3-3H]glucose and 2-deoxy-D-[1-14C]glucose were determined following 476 
deproteinization of plasma samples as previously described78. For the determination of tissue 2-477 
[14C]DG-6-phosphate (2-[14C]DG-6-P) content, tissue samples were homogenized, and the 478 
supernatants were subjected to an ion exchange column to separate 2-[14C]DG-6-P from 2-479 
[14C]DG. Glucose uptake in individual tissues was assessed by determining the tissue content of 480 
2-[14C]DG-6-P and plasma 2-[14C]DG profile. 481 
Molecular analysis using tissues collected from in vivo infusion experiments  482 
The following molecular analysis (insulin signaling, RNA isolation, and RT-qPCR) was 483 
performed using tissue samples collected from in vivo infusion experiments at the National MMPC 484 
at UMass Medical School. Male C57BL/6J mice received a continous infusion of insulin (0.015 485 
nmol//kg/min) or GIV dcVILP (0.75 nmol/kg/min), or saline (n = 4-6) for 3 hours, and 20% 486 
glucose was infused at variable rates to maintain euglycemia. Blood samples were collected from 487 
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the tail tip at 10-20 min intervals during the experiments. Basal tissue samples were collected after 488 
a 3 hour infusion of saline in awake mice. 489 
 490 
In vivo insulin signaling  491 
Tissues were lysed in RIPA buffer (EMD Millipore) supplemented with 0.1% SDS and a cocktail 492 
of protease and phosphatase inhibitors (Biotools). Proteins were denatured in denaturing buffer 493 
(NuPAGE LDS Sample Buffer, Thermo Fisher Scientific) supplemented with 5% of β-494 
mercaptoethanol and incubated at 90°C for 5 minutes. 10 µg/well of protein was loaded on a 4-495 
12% NuPAGE Bis-tris gel (Thermo Fisher Scientific) and then transferred on PVDF membrane 496 
(Thermo Fisher Scientific). Membrane was blocked in blocking buffer (Thermo Fisher Scientific) 497 
for 1h at room temperature and incubated with primary antibody (1:1000) over-night and with 498 
secondary antibody (1:1000) for 4 hours. The membranes were probed with the following 499 
antibodies: IRβ (#3025S), phospho-IR/IGF1R (#3024L), Akt (#4685) and phospho-Akt (S473) 500 
(#4060) from  Cell Signaling Technology and goat anti-rabbit HRP conjugate (#1706515) from 501 
Bio-Rad. Protein detection was realized using a mix of a luminol solution and a peroxide solution 502 
(1:1) (Thermo Fisher Scientific). Protein bands were detected with a ChemiDoc MP Imaging 503 
System (Bio-Rad) and quantified with ImageJ. 504 
 505 
RNA isolation 506 
Tissues were homogenized in 1 ml of QIAzol Lysis Reagent (Qiagen) using 0.1 mm dia 507 
Zirconia/Silica beads (Biospec) and Minibeadbeater (Biospec). After homogenization, samples 508 
were incubated for 5 min at RT, centrifuged (12000g, 10 min, 4°C) and supernatant was transferred 509 
to a new tube. In the case of BAT and WAT, an additional centrifugation step was included and 510 
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the upper fatty layer was avoided when transferred to new tubes. 200 µl of chloroform (Sigma-511 
Aldrich) was added, the samples were vortexed for 15s, incubated for 5 min at RT and centrifuged 512 
(12000g, 15 min, 4°C). The aqueous phase was transferred to new tubes, 100% ethanol in ratio 1:1 513 
was added and subsequently the Direct-zol RNA Miniprep Kit (Zymo Research) was used 514 
according to the manufacturer’s instructions.  515 
RT-qPCR 516 
DNAse treatment and cDNA synthesis was performed using the SuperScriptTM IV VILOTM Master 517 
Mix with ezDNAse (Invitrogen) according to manufacturer’s instructions. The qPCR was 518 
performed using Power SYBR® Green PCR Master Mix (Applied Biosystems) according to 519 
manufacturer’s instructions on QuantStudio 3 (Applied Biosystems). The primers used are listed 520 
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Figure legends 744 
Figure 1: dcVILPs share significant homology in structure with human insulin and IGF-1. 745 
A: Sequence alignment of synthesized dcVILPs with human insulin and IGF-1. The residues 746 
important for receptor binding are highlighted with different colors. Site1a and Site1b are as 747 
described in24.  B - E: Overlay of a model of GIV and LCDV-1 dcVILPs and insulin/IGF-1 bound 748 
to Site 1 of IR/IGF1R. Side chains of fully conserved amino acids are shown (main chain is shown 749 
for glycine). Insulin is in yellow, IGF-1 is in cyan, GIV dcVILP is in orange, LCDV-1 dcVILP is 750 
in green, IR is in grey, IGF1R is in pink. 751 
 752 
Figure 2: dcVILPs bind to human IR-A, IR-B and IGF1R and stimulate insulin signaling. A 753 
- C: Binding competition dose response curves. The curves are showing the ability of dcVILPs to 754 
compete with 125-I labeled human insulin for binding to IR-A (A) and IR-B (B) and with 125-I 755 
labeled human IGF-1 for binding to IGF1R (C). IM-9 cells were used for measurements on IR-A, 756 
while murine embryonic fibroblasts derived from IGF-1 knock-out mice and stably transfected 757 
with either human IR-B or human IGF1R were used for measurements on these receptors. A 758 
representative curve for each peptide to each receptor is shown. Each point represents the mean ± 759 
SEM of duplicates. Every experiment was repeated at least three times. D - F: Insulin signaling 760 
via IR-A (D), IR-B (E) and IGF1R (F). Murine embryonic fibroblasts derived from IGF-1 knock-761 
out mice and stably transfected with either human IR-A, IR-B or human IGF1R were used for the 762 
experiment. Phosphorylation of the specific receptor, Akt and Erk1/2 was observed in 15 minutes 763 
after stimulation. Exposure times were between 30s to 1 min. High exposure time (HE) was 5 min. 764 
 765 
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Figure 3: GIV and SGIV dcVILPs stimulate glucose uptake in mice. A – D: Insulin tolerance 766 
test. C57BL/6J mice were injected i.p with human insulin, human IGF-1, GIV and SGIV dcVILPs 767 
or saline. The concentration of insulin was 6 nmol/kg in all panels, whereas the concentration of 768 
dcVILPs was 0.3 µmol/kg (A) and 60 nmol/kg (B, D). Concentration of human IGF-1 was 60 769 
nmol/kg (C, D).  Blood glucose was measured within the range from 0 to 180 minutes. Data are 770 
mean ± S.E.M. (*P<0.05; **P<0.01, *** P < 0.001). Mixed-effects analysis followed by Dunnett’s 771 
multiple comparisons test was applied, n = 5 in all groups. E: Glucose infusion rates during the 2-772 
hour in vivo experiments with infusion of human insulin or GIV dcVILP. The concentration of 773 
insulin was 0.015 nmol/kg/min, and the concentration of GIV dcVILP was 0.15 and 1.5 774 
nmol/kg/min. n = 4 for insulin and n = 2 for both concentrations of GIV dcVILP. F: Glucose 775 
infusion rates during the 3-hour in vivo experiments with infusion of human insulin or GIV 776 
dcVILP. The concentration of insulin was 0.015 nmol/kg/min, and the concentration of dc GIV 777 
dcVILP was 0.75 nmol//kg/min. n = 4 for both groups. Two-way repeated measures ANOVA 778 
followed by Tukey’s multiple comparisons test was applied. Data are mean ± S.E.M (*P<0.05; 779 
**P<0.01).  780 
 781 
Figure 4: GIV dcVILP stimulates in vivo insulin signaling and WAT specific glucose uptake. 782 
A - D: Tissue-specific glucose uptake after a 3-hour infusion of insulin (0.015 nmol/kg/min; 1x) 783 
or GIV dcVILP (0.75 nmol//kg/min; 50x) in awake mice (n=5 for each group). Student’s t-test was 784 
applied (**P<0.01). n=5 for both groups.  E – G: in vivo signaling in insulin sensitive tissues 785 
obtained at the end of 3-hour infusion of insulin (0.015 nmol/kg/min; 1x) or GIV dcVILP (0.75 786 
nmol//kg/min; 50x) in awake mice. Basal tissue samples were collected after a 3-hour saline 787 
infusion. E: liver, F: skeletal muscle (gastrocnemius), G: WAT (epididymal).  788 
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Figure 5: RT-qPCR analysis of expression of genes connected with insulin function and 789 
lipogenesis in murine WAT. Tissues were collected after 3-hour insulin (0.015 nmol/kg/min; 1x) 790 
or GIV VILP (0.75 nmol/kg/min; 50x) infusion, and basal tissue samples were collected after 3 791 
hours of saline infusion in awake mice. Data are expressed as % of β-actin. n = 4 per group. 792 
Ordinary one-way ANOVA followed by Tukey’s multiple comparison test was applied (*P<0.05; 793 
**P<0.01, ***P<0.001). P-values lower than 0.1 are indicated. 794 
 795 
Figure 6: RT-qPCR analysis of expression of genes connected with insulin function, and 796 
lipogenesis in murine liver. Tissues were collected after 3-hour insulin (0.015 nmol/kg/min; 1x) 797 
or GIV VILP (0.75 nmol/kg/min; 50x) infusion, and basal tissue samples were collected after 3 798 
hours of saline infusion in awake mice. Data are expressed as % of β-actin. n = 4 per group. 799 
Ordinary one-way ANOVA followed by Tukey’s multiple comparison test was applied (*P<0.05; 800 
**P<0.01, ***P<0.001, ****P<0.001). P-values lower than 0.1 are indicated. 801 
 802 
Figure S1: Sequence alignment of synthesized dcVILPs with human insulin and IGF-1. 803 
Comparison of dcVILPs with human insulin is shown in A and comparison with human IGF-1 is 804 
shown in B. Cysteine residues important for correct folding which are conserved in all peptides 805 
are highlighted in yellow. Three residues that differ between GIV and SGIV dcVILPs are marked 806 
in red. Conserved residues are marked by asterisk, conservatively substituted residues are marked 807 
by colon and semi-conservatively substituted residues are marked by period 808 
 809 
.CC-BY-NC-ND 4.0 International license(which was not certified by peer review) is the author/funder. It is made available under a
The copyright holder for this preprintthis version posted August 22, 2020. . https://doi.org/10.1101/2020.08.21.261321doi: bioRxiv preprint 
34 
 
Figure S2: Quantification of the western blot result showing in vivo insulin signaling after in 810 
vivo experiments. Tissues were collected after 3 hours of insulin or 50x GIV VLIP infusion, and 811 
basal tissue samples were collected after 3 hours of saline infusion in awake mice. A, C, E: 812 
IR/IGF1R phosphorylation in liver, skeletal muscle (gastrocnemius) and WAT (epididymal), 813 
respectively. B, D, F: Akt phosphorylation in liver, skeletal muscle (gastrocnemius) and WAT 814 
(epididymal), respectively. n = 6 for saline, n = 4 for insulin, n = 5 for GIV dcVILP in the case of 815 
liver and skeletal muscle, n = 4 for GIV dcVILP in the case of WAT. Ordinary One-Way ANOVA 816 
followed by Tukey’s multiple comparison test was applied ((*P<0.05; **P<0.01, ***P<0.001).  817 
 818 
Figure S3: RT-qPCR analysis of IR-A, IR-B and IGF1R expression in murine liver, skeletal 819 
muscle (quadriceps), BAT and WAT.  Data are expressed as % of β-actin. n = 4 per group. 820 
 821 
Figure S4: RT-qPCR analysis of expression of genes regulated by insulin action in murine 822 
skeletal muscle (quadriceps) after in vivo experiments. Tissues were collected after 3-hour 823 
insulin (0.015 nmol/kg/min; 1x) or GIV VILP (0.75 nmol/kg/min; 50x) infusion, and basal tissue 824 
samples were collected after 3 hours of saline infusion in awake mice. Data are expressed as % of 825 
β-actin. n = 4 per group. Ordinary one-way ANOVA followed by Tukey’s multiple comparison 826 
test was applied (*P<0.05; **P<0.01, ***P<0.001). P-values lower than 0.1 are indicated. 827 
 828 
Figure S5: RT-qPCR analysis of expression of genes regulated by insulin action in murine 829 
BAT after in vivo experiments. Tissues were collected after 3-hour insulin (0.015 nmol/kg/min; 830 
1x) or GIV VILP (0.75 nmol/kg/min; 50x) infusion, and basal tissue samples were collected after 831 
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3 hours of saline infusion in awake mice. Data are expressed as % of β-actin. n = 4 per group. 832 
Ordinary one-way ANOVA followed by Tukey’s multiple comparison test was applied (*P<0.05; 833 
**P<0.01, ***P<0.001). P-values lower than 0.1 are indicated. 834 
 835 
Figure S6: Overlay of a model of dcVILPs and insulin/IGF-1 bound to IR and IGF1R.  836 
A: Model of GIV and SGIV dcVILPs bound to Site 1 of IR. Insulin positions B28 (insulin and 837 
dcVILPs), B29 and B30 (dcVILPs) are shown. B: Model of GIV dcVILP bound to Site 2 of IR. 838 
Insulin positions GluB13 and HisB10 and their substituted counterparts in GIV dcVILP are shown. 839 
C: Model of GIV dcVILP bound to Site 1 of IGF1R. IGF1R positions Glu9 and Asp12 and their 840 
identical counterparts in GIV dcVILP are shown. Insulin is in yellow, IGF-1 is in magenta, GIV 841 
dcVILP is in orange and SGIV dcVILP is in pink. IR is in grey and IGF1R is in pink. The α-CT 842 
peptide is shown in light blue in all cases. 843 
 844 
Table Legends 845 
 846 
Table 1: Comparison of conserved residues among human insulin, human IGF-1 and 847 
dcVILPs. Percentage of amino-acid residues that GIV, SGIV and LCDV-1 dcVILPs share with 848 
human insulin and IGF-1 is shown in upper panel.  Percentage of important amino-acids that are 849 
important for receptor binding in dcVILPs is shown in lower panel.  850 
 851 
Table 2: Receptor binding affinities of human insulin, human IGF-1 and dcVILPs to human 852 
IR-A, IR-B and IGF1R receptors. Binding affinity is reported by the equilibrium dissociation 853 
constant (Kd). The Kd values were obtained from at least three independent measurements 854 
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(indicated as n). Relative binding affinity is defined as Kd of human insulin or IGF-1/Kd of ligand 855 
of interest.  856 
 857 
TableS1: Whole body metabolism data measured in the 3-hour in vivo infusion experiments 858 
in awake mice. n = 5 for both groups. 859 
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Residues interacting with primary IR (hIns) and IGF-1R (hIGF-1) binding site (Site 1a)
Residues interacting with primary IR (hIns) and IGF-1R (hIGF-1) binding site (Site 1b)
Residues interacting with secondary IR binding site (Site 2)
Residues that are conserved in VILPs
Residues that are conservatively substituted in VILPs





Insulin + dc GIV, IR Insulin + dc LCDV-1, IR
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Human insulin, 6 nmol/kg (1x)
dc GIV, 0.3 mol/kg (50x)











































dc SGIV VILP, 60 nmol/kg (10x)
dc GIV VILP, 60 nmol/kg (10x)
Human insulin, 6 nmol/kg (1x)






























Human insulin, 6 nmol/kg (1x)
Human IGF-1, 60 nmol/kg (10x)
dc SGIV VILP, 60 nmol/kg (10x)












** * * *






























Human insulin, 6 nmol/kg (1x)





















Human insulin, 0.015 nmol/kg/min (1x)
dc GIV, 0.15 nmol/kg/min (10x)
dc GIV, 1.5 nmol/kg/min (100x)
** **














Human insulin, 0.015 nmol/kg/min (1x)
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In vivo insulin signaling
Saline                                Insulin (1x)                   dc GIV (50x)
Saline                                 Insulin (1x)                      dc GIV (50x)
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Insulin + dc GIV VILP, IR Site 2 IGF-1 + dc GIV VILP, IGF1R Site 1














.CC-BY-NC-ND 4.0 International license(which was not certified by peer review) is the author/funder. It is made available under a
The copyright holder for this preprintthis version posted August 22, 2020. . https://doi.org/10.1101/2020.08.21.261321doi: bioRxiv preprint 
Table 1 
  
A-chain/domain   B-chain/domain  
  dc GIV dc SGIV dc LCDV-1     dc GIV dc SGIV dc LCDV-1 
Insulin  38% 38% 52%   Insulin  30% 33% 47% 
IGF-1  38% 38% 43%   IGF-1  45% 45% 59% 
                  
Site 1 binding residues    Site 2 binding residues  
  dc GIV dc SGIV dc LCDV-1     dc GIV dc SGIV dc LCDV-1 
IR 71% 71% 59%   IR 43% 43% 64% 
IGF1R 52% 52% 48%   IGF1R - - - 
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IR-A   IR-B   IGF1R 
Kd [nM]  









Kd [nM]  










Kd [nM]  










0.52 ± 0.03 
1 202 
  0.58 ± 0.07 
1 303 
  293 ± 101 
0.0008 1 
(5)   (3)   (3) 
Human 
IGF-1 
105 ± 19 
0.005 1 
  176 ± 22 
0.003 1 
  0.24 ± 0.13 
1 1221 
(4)   (3)   (3) 
dc GIV  
315 ± 81 
0.002 0.33 
  1179 ± 625 
0.0005 0.15 
  41.3 ± 11.6 
0.006 7.09 
(3)   (3)   (3) 
dc SGIV  
102 ± 29 
0.005 1.02 
  1441 ± 558 
0.0004 0.12 
  28.6 ± 10.0 
0.008 10.2 




at 10-6 M 
(3) 
- - 




at 10-6 M 
 - - 
  (3)   (3) 
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Table S1 
Insulin - 0.015 nmol/kg/min (male; n=5) 
        
    Glucose   Hepatic  
Whole 
Body 
   
 Body Basal Clamp Infusion Basal Clamp Insulin Glucose  Glycogen Fat Lean 
 Weight Glucose Glucose Rate HGP HGP Action Turnover Glycolysis Synthesis Mass Mass 
 (g) (mg/dl) (mg/dl) (mg/kg/m) (mg/kg/m) (mg/kg/m) (%) (mg/kg/m) (mg/kg/m) (mg/kg/m) (g) (g) 
1 25 175 99 59.3 26.5 11.6 56.2 70.9 59.3 11.6 1.3 26.8 
2 24 149 125 60.3 15.6 9.8 37.1 70.2 55.3 14.8 1.2 26.3 
3 23 131 121 55.9 16.6 8.3 49.9 64.2 44.6 19.6 2.3 23.9 
4 24 175 129 65.1 21.1 1.3 93.9 66.4 44.3 22.1 1.3 26.0 
5 22 169 126 50.9 19.3 0.5 97.3 51.5 31.6 19.9 1.2 24.0 
             
Avg 24 160 120 58.3 19.8 6.3 66.9 64.6 47.0 17.6 1.4 25.4 
SE 0 9 5 2.4 1.9 2.3 12.1 3.5 4.9 1.9 0.2 0.6 
             
             
             
GIV dcVILP - 0.75 nmol/kg/min (male; n=5)  
        
    Glucose   Hepatic  
Whole 
Body 
   
 Body Basal Clamp Infusion Basal Clamp Insulin Glucose  Glycogen Fat Lean 
 Weight Glucose Glucose Rate HGP HGP Action Turnover Glycolysis Synthesis Mass Mass 
 (g) (mg/dl) (mg/dl) (mg/kg/m) (mg/kg/m) (mg/kg/m) (%) (mg/kg/m) (mg/kg/m) (mg/kg/m) (g) (g) 
1 25 180 96 61.3 20.5 0.2 98.8 61.6 42.5 19.1 0.9 27.2 
2 25 182 101 77.2 19.1 0.7 96.3 77.9 73.0 4.9 1.3 26.9 
3 23 213 112 67.3 20.7 9.8 52.6 77.2 44.3 32.9 0.8 26.5 
4 23 156 117 75.6 14.5 -7.1 100.0 68.5 43.7 24.8 1.3 24.5 
5 24 145 125 63.5 11.7 8.0 31.9 71.5 49.5 22.0 1.4 24.8 
             
Avg 24 175 110 69.0 17.3 2.3 75.9 71.3 50.6 20.7 1.2 26.0 
SE 0 12 5 3.2 1.8 3.0 14.1 3.0 5.7 4.6 0.1 0.6 
T-
test 
0.545 0.323 0.230 0.028 0.367 0.323 0.639 0.187 0.650 0.545 0.293 0.508 
vs. Insulin            
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Protein   Primers Reference 
IR-A and IR-B    
  Forward TCC TGA AGG AGC TGG AGG AGT 1 
IR-A      
  Reverse CTT TCG GGA TGG CCT GG 1 
IR-B      
  Reverse TTC GGG ATG GCC TAC TGT C 1 
IGF1R      
  Forward GGC ACA ACT ACT GCT CCA AAG AC 1 
  Reverse CTT TAT CAC CAC CAC ACA CTT CTG  
Acetyl-CoA carboxylase-1    
  Forward GAA GTC AGA GCC ACG GCA CA 2 
  Reverse GGC AAT CTC AGT TCA AGC CAG TC  
Lipoprotein lipase     
  Forward GGG AGT TTG GCT CCA GAG TTT 3 
  Reverse TGT GTC TTC AGG GGT CCT TAG  
Fatty acid synthase    
  Forward CTC TGA TCA GTG GCC TCC TC 4 
  Reverse TGC TGC AGT TTG GTC TGA AC  
GLUT4       
  Forward ACC GGA TTC CAT CCC ACA AG 3 
  Reverse TCC CAA CCA TTG AGA AAT GAT GC  
SREBP-1c      
  Forward CGG AAG CTG TCG GGG TAG  5 
  Reverse GTT GTT GAT GAG CTG GAG CA   
UCP-1      
  Forward GGG CAT TCA GAG GCA AAT CAG  6 
  Reverse CTG CCA CAC CTC CAG TCA TTA AG   
Glucose-6-phosphatase, catalytic subunit  
  Forward GAT TGC TGA CCT GAG GAA CG 7 
  Reverse ATA GTA TAC ACC TGC TGC GCC  
Phosphoenolpyruvate carboxykinase 1  
  Forward GCA TAA CGG TCT GGA CTT CT 7 
  Reverse TGA TGA CTG TCT TGC TTT CG  
Glucokinase      
  Forward GAG ATG GAT GTG GTG GCA AT 4 
  Reverse ACC AGC TCC ACA TTC TGC AT  
β-Actin      
  Forward AGC CAT GTA CGT AGC CAT CCA 8 
  Reverse TCT CCG GAG TCC ATC ACA ATG   
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